<DOC>
	<DOCNO>NCT02838537</DOCNO>
	<brief_summary>This study conduct retrospective study expose unexposed cohort French population include beneficiary age 65 old . Exposed patient match non expose control accord age , gender area residence ( ratio 1/4 ) . Two exposed arm two non expose control arm plan . Triptan arm user triptan define least one record dispense drug follow , record drug previous 6 month ( `` new incident user '' ) . Ergot arm user ergot derivative define least one record dispense drug follow , record drug previous 6 month ( `` new incident user '' ) . This study involve data French National Health Insurance Information System ( Système National d‟Information Inter-Régimes de l‟Assurance Maladie ; SNIIRAM ) link French hospital discharge database ( Programme de Médicalisation de Systèmes d‟Informations , PMSI ) . - The SNIIRAM vast national medico-administrative database represent part French population , allow identify describe precisely medication dispensation ( name drug , date dispense quantity ) include triptans reimbursed medication . - The PMSI provide medical information patient admit hospital France , include discharge diagnosis encode accord ICD-10 , medical procedure French diagnosis-related group The research propose expect provide update nationally-consolidated estimation cardiovascular risk associate triptans use elderly population .</brief_summary>
	<brief_title>TRiptan Use Serious Vascular Events Elderly Over 65 Years</brief_title>
	<detailed_description />
	<criteria>Patients age 65 Patients register SNIIRAM To avoid depletion susceptibles bias , incident user include . Incident user define lack reimbursement triptan ( ergot derivative ) prior six month study period . exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Triptan</keyword>
	<keyword>Drug utilization</keyword>
	<keyword>Elderly</keyword>
	<keyword>Drug abuse</keyword>
	<keyword>Cardiovascular disease</keyword>
</DOC>